Pulmatrix Inc (PULM) USD0.0001

Sell:$7.25Buy:$8.40$0.34 (4.49%)

Prices delayed by at least 15 minutes
Sell:$7.25
Buy:$8.40
Change:$0.34 (4.49%)
Prices delayed by at least 15 minutes
Sell:$7.25
Buy:$8.40
Change:$0.34 (4.49%)
Prices delayed by at least 15 minutes

Company Information

About this company

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

Key people

Peter B. Ludlum
Interim Chief Executive Officer and Interim Chief Financial Officer
Michael J. Higgins
Independent Chairman of the Board
Richard Batycky
Independent Director
Todd M. Bazemore
Independent Director
Christopher H. Cabell
Independent Director
Anand Varadan
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US74584P3010
  • Market cap
    $26.99m
  • Employees
    22
  • Shares in issue
    3.65m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.